Oncotype DX Recurrence Score in HER2-Negative, ER/PR-Positive Breast Cancer: A Preliminary Study and the First Iraqi Experience

Introduction: The Oncotype DX recurrence score (RS) is a key determinant in guiding chemotherapy decisions for hormone receptor-positive, HER2-negative breast cancer patients. This study examines RS distribution, its correlation with clinical variables, and its impact on treatment recommendations in an Iraqi cohort. Methods: a total of 383 patients with classified in to tow age group <50 years (107) and ≥50 years (276), mean, and Standard deviations were calculated for each age group. An independent samples t-test and chi square test was used test if there was significant difference in mean of RS between these independent groups <50 vs. ≥50 years. Results: A retrospective cohort analysis was conducted using patient records from oncology clinics. Patients were stratified into two age groups (<50 and ≥50), and Recurrence Scores (RS) were classified into low (0–10), intermediate (11–25), and high (≥26) categories. Statistical analyses included descriptive statistics, Conclusion: RS plays a critical role in chemotherapy decision-making for HER2-negative, ER/PR-positive breast cancer. Younger patients demonstrate higher recurrence scores, underscoring the need for personalized treatment strategies in Iraq. These findings contribute to regional oncology research by refining recurrence risk assessments and supporting evidence-based precision medicine approaches.